Last reviewed 2026-04-19 · How we verify

ASPOXICILLIN

Phase 2 active Small molecule

ASPOXICILLIN is a aspoxicillin drug. It is currently in Phase 2 development.

ASPOXICILLIN works by inhibiting the synthesis of the bacterial cell wall, ultimately leading to cell lysis and death.

ASPOXICILLIN is a small molecule antibiotic drug of the aspoxicillin class. Its mechanism of action involves inhibiting bacterial cell wall synthesis, specifically targeting penicillin-binding proteins. However, due to the lack of available information, its target, approved indications, and commercial status are unknown. Further research is needed to determine its efficacy and safety profile. As a result, it is not possible to provide a comprehensive summary of its clinical use.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ASPOXICILLIN
Drug class	aspoxicillin
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of the bacterial cell wall like a strong, protective shield. ASPOXICILLIN blocks the production of this shield, making it difficult for the bacteria to maintain its structure and ultimately leading to its demise. This allows the body's immune system to more effectively fight off the infection.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASPOXICILLIN CI brief — competitive landscape report
ASPOXICILLIN updates RSS · CI watch RSS

Frequently asked questions about ASPOXICILLIN

What is ASPOXICILLIN?

ASPOXICILLIN is a aspoxicillin drug.

How does ASPOXICILLIN work?

ASPOXICILLIN works by inhibiting the synthesis of the bacterial cell wall, ultimately leading to cell lysis and death.

What drug class is ASPOXICILLIN in?

ASPOXICILLIN belongs to the aspoxicillin class. See all aspoxicillin drugs at /class/aspoxicillin.

What development phase is ASPOXICILLIN in?

ASPOXICILLIN is in Phase 2.

Drug class: All aspoxicillin drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing